Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product
0-9 years 10-17 years 18-26 years
Condition: Non Hodgkin Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
(Trial terminated: Eligible subjects will be enrolled in Celgene’s long-term follow-up protocol for subjects previously treated with a CAR T-cell product.)
This study will provide long-term follow-up for patients who have received treatment with a Juno CAR T-cell product in a Juno-sponsored clinical trial. In this study, patients will be followed for up to 15 years after their last dose of Juno CAR T cells for evaluation of delayed adverse events, presence of persisting CAR T-cell vector sequences, presence of replication-competent retrovirus (RCR) or lentivirus (RCL), and survival.